Abstract Search

ey0019.11-14 | Weight regulation and endocrine circuits (including interventions) | ESPEYB19

11.14. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist

A Shoemaker , H Silver , M Buchowski , J Slaughter , J Yanovski , C Elfers , C Roth , MJ Abuzzahab

Ashley.H.Shoemaker@VUMC.org International Journal of Obesity 2022, Epub 2022 Jan 3. doi: 10.1038/s41366-021-01043-6. https://pubmed.ncbi.nlm.nih.gov/34975146/Brief Summary: This double-blind, placebo-controlled trial assessed the efficacy of 36 weeks of GLP1RA treatment with exenatide e...

0 shares

ey0021.11-4 | Interventions for Weight Loss: New Findings | ESPEYB21

11.4. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial

CL Roth , C Scimia , AH Shoemaker , M Gottschalk , J Miller , G Yuan , S Malhotra , MJ Abuzzahab

Brief Summary: This phase 2, open-label, multicenter trial examined the efficacy of setmelanotide, a melanocortin-4 receptor agonist, in patients aged 6 to 40 years with obesity due to hypothalamic injury. Setmelanotide reduced body mass index (BMI) and hunger levels in most participants; 89% achieved a reduction in BMI of at least 5% after 16 weeks. These results indicate that setmelanotide is a promising treatment for hypothalamic obesity.This phase 2 ...

0 shares

ey0016.14-4 | (1) | ESPEYB16

14.4. A reprogramming human T cell function and specificity with non-viral genome targeting

TL Roth , C Puig-Saus , R Yu , E Shifrut , J Carnevale , PJ Li , Hiatt , J Saco , P Krystofinski , H Li , V Tobin , DN Nguyen , MR Lee , AL Putnam , AL Ferris , JW Chen , JN Schickel , L Pellerin , D Carmody , G Alkorta-Aranburu , D Del Gaudio , H Matsumoto , M Morell , Y Mao , M Cho , RM Quadros , CB Gurumurthy , B Smith , M Haugwitz , SH Hughes , JS Weissman , K Schumann , JH Esensten , AP May , A Ashworth , GM Kupfer , SAW Greeley , R Bacchetta , E Meffre , MG Roncarolo , N Romberg , KC Herold , A Ribas , MD Leonetti , A Marson

To read the full abstract: Nature. 2018 Jul;559(7714):405409This article decries a CRISPR-Cas9 genome-targeting system that does not require viral vectors, allowing rapid and efficient insertion of large DNA sequences at specific sites in the genomes of primary human T cells, while preserving cell viability and function.The common approach to genetically...

1 shares

ESPE Yearbook of Paediatric Endocrinology

11.14. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist

11.4. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial

14.4. A reprogramming human T cell function and specificity with non-viral genome targeting

BiosciAbstracts